摘要
目的:研究探讨信迪利单抗联合替莫唑胺治疗胶质母细胞瘤的效果及对p53蛋白、骨形成蛋白(BMP)、Xklp2靶蛋白(TPX2)的影响。方法:选取2020年1月-2022年1月佳木斯市中心医院收治的106例胶质母细胞瘤患者,用电脑随机抽签法分为对照组、观察组,各53例。对照组以替莫唑胺治疗,观察组以替莫唑胺联合信迪利单抗治疗。评估比较两组临床疗效、血清学指标、免疫功能指标、生活质量、治疗安全性。结果:观察组的客观缓解率(ORR)、疾病控制率(DCR)均高于对照组(P<0.05)。治疗后观察组的p53蛋白、BMP、TPX2表达水平均低于对照组(P<0.05)。治疗后观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于对照组,CD8^(+)则低于对照组(P<0.05)。治疗后观察组的欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)各项评分均高于对照组(P<0.05)。治疗期间两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:信迪利单抗联合替莫唑胺治疗胶质母细胞瘤有较好的效果,能够抑制p53蛋白、BMP、TPX2表达,提高患者机体免疫功能,改善患者的生活质量,安全性较好,可临床推荐。
Objective:To investigate the efficacy of Sintilimab combined with Temozolomide in the treatment of glioblastoma and its effect on the expression of p53 protein,bone morphogenetic protein (BMP) and Xklp2 target protein (TPX2).Method:A total of 106 patients with glioblastoma treated in Jiamusi Central Hospital from January2020 to January 2022 were randomly divided into a control group and an observation group by computer balloting,53cases in each group.The control group was treated with Temozolomide,and the observation group was treated with Temozolomide combined with Sindilizumab.The clinical efficacy,serological indexes,immune function indexes,quality of life and treatment safety of the two groups were evaluated and compared.Result:The objective remission rate (ORR) and disease control rate (DCR) in the observation group were higher than those in the control group(P<0.05).After treatment,the expression levels of p53 protein,BMP and TPX2 in the observation group were lower than those in the control group (P<0.05).After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,while CD8^(+) was lower than that in the control group (P<0.05).After treatment,the scores of European organization for research and treatment of cancer quality of life questionnare-core 30(EORTC QLQ-C30) in the observation group were higher than those in the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during the treatment (P>0.05)Conclusion:Sintilimab combined with Temozolomide has good effect in the treatment of glioblastoma,and it can inhibit the expression of p53 protein,BMP and TPX2,improve the immune function of patients,and improve the quality of life of patients,the safety is good,and it can be clinically recommended.
作者
王廉
WANG Lian(Jiamusi Central Hospital,Heilongjiang Province,Jiamusi 154002,China)
出处
《中国医学创新》
CAS
2022年第35期5-9,共5页
Medical Innovation of China
